ArriVent BioPharma, Inc. Common Stock – NASDAQ:AVBP

Add to watchlist

$18.6

-8.66

-31.77%

Market closed

Open in about 7 hours

+48.23%

month

+48.23%

quarter

Market Cap	860.28M
Enterprise value	N/A

P/E	N/A
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	N/A
Price/Book	N/A
PEG ratio	N/A
EPS	N/A

Revenue	N/A
EBITDA	N/A
Income	N/A
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

ArriVent BioPharma, Inc. Common Stock (NASDAQ:AVBP): Profit margin
2023	0	-69.33M

ArriVent BioPharma, Inc. Common Stock (NASDAQ:AVBP): Earnings per share (EPS)
2024-05-08	-0.84	-0.7

ArriVent BioPharma, Inc. Common Stock (NASDAQ:AVBP): Debt to assets
2023	163098000	11.80M	7.24%

ArriVent BioPharma, Inc. Common Stock (NASDAQ:AVBP): Cash Flow
2022	-43.63M	0	169.72M
2023	-55.84M	0	42.85M

ArriVent BioPharma, Inc. Common Stock alternative data

ArriVent BioPharma, Inc. Common Stock
Employees

ArriVent BioPharma, Inc. Common Stock (NASDAQ:AVBP): Employee count
Feb 2024	42
Mar 2024	42
Apr 2024	40
May 2024	40
Jun 2024	40
Jul 2024	40
Dec 2024	40

ArriVent BioPharma, Inc. Common Stock
Insider Trading

ArriVent BioPharma, Inc. Common Stock (NASDAQ:AVBP): Insider trades (number of shares)
Period	Buy	Sel
Jan 2024	222222	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value	Source
Purchase	30 Jan 2024	GORDON CARL L director, 10 percent owner: director, 10 percent owner:	Common Stock	222,222	$18	$3,999,996

AVBP insider trading transactions

ArriVent BioPharma, Inc. Common Stock
Latest News

Wednesday, 6 November 2024
08:30	Discover the 3 Best-Performing Biotech IPO Stocks of 2024	marketbeat.com
Monday, 9 September 2024
12:05	ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer	globenewswire.com
Monday, 19 August 2024
10:55	Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 27.26%: Read This Before Placing a Bet	zacks.com
Thursday, 15 August 2024
07:01	Aarvik Therapeutics Announces Option Exercise by Collaboration Partner ArriVent BioPharma	businesswire.com
Wednesday, 14 August 2024
16:01	ArriVent BioPharma Reports Second Quarter 2024 Financial Results	globenewswire.com
Monday, 12 August 2024
08:00	ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer	globenewswire.com
Wednesday, 5 June 2024
07:00	ArriVent Announces a Multi-Target ADC Collaboration with Alphamab	globenewswire.com
Thursday, 16 May 2024
16:05	ArriVent Appoints John Hohneker, M.D., to its Board of Directors	globenewswire.com
Wednesday, 8 May 2024
08:00	ArriVent BioPharma Reports First Quarter 2024 Financial Results	globenewswire.com
Monday, 22 April 2024
16:05	ArriVent Appoints Kristine Peterson to its Board of Directors	globenewswire.com
Thursday, 28 March 2024
20:30	InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib	businesswire.com
16:05	ArriVent BioPharma Reports Full Year 2023 Financial Results	globenewswire.com
Monday, 5 February 2024
12:09	Insider Buying at These Biotechs Is Huge	247wallst.com
Monday, 29 January 2024
18:15	ArriVent Wows Investors With Promising China-Developed Lung Cancer Treatment	Seeking Alpha

Frequently Asked Questions (FAQ)

What's the price of ArriVent BioPharma, Inc. Common Stock stock today?

One share of ArriVent BioPharma, Inc. Common Stock stock can currently be purchased for approximately $18.6.
When is ArriVent BioPharma, Inc. Common Stock's next earnings date?

Unfortunately, ArriVent BioPharma, Inc. Common Stock's (AVBP) next earnings date is currently unknown.
Does ArriVent BioPharma, Inc. Common Stock pay dividends?

No, ArriVent BioPharma, Inc. Common Stock does not pay dividends.
How much money does ArriVent BioPharma, Inc. Common Stock make?

ArriVent BioPharma, Inc. Common Stock has a market capitalization of 860.28M. ArriVent BioPharma, Inc. Common Stock made a loss 69.33M US dollars in net income (profit) last year or -$0.7 on an earnings per share basis.
What is ArriVent BioPharma, Inc. Common Stock's stock symbol?

ArriVent BioPharma, Inc. Common Stock is traded on the NASDAQ under the ticker symbol "AVBP".
What is ArriVent BioPharma, Inc. Common Stock's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of ArriVent BioPharma, Inc. Common Stock?

Shares of ArriVent BioPharma, Inc. Common Stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
How many employees does ArriVent BioPharma, Inc. Common Stock have?

As Dec 2024, ArriVent BioPharma, Inc. Common Stock employs 40 workers.
When ArriVent BioPharma, Inc. Common Stock went public?

ArriVent BioPharma, Inc. Common Stock is publicly traded company for just a year since IPO on 26 Jan 2024.
What is ArriVent BioPharma, Inc. Common Stock's official website?

The official website for ArriVent BioPharma, Inc. Common Stock is arrivent.com.
How can i contact ArriVent BioPharma, Inc. Common Stock?

ArriVent BioPharma, Inc. Common Stock can be reached via phone at +62 82774836.

ArriVent BioPharma, Inc. Common Stock

arrivent.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

+62 82774836

18 Campus Boulevard
Newtown Square, 19073

:
ISIN: US04272N1028
: